Literature DB >> 2452186

HIV-1-specific production of IFN-gamma and modulation by recombinant IL-2 during early HIV-1 infection.

C Rinaldo1, P Piazza, Y Z Wang, J Armstrong, P Gupta, M Ho, S Petteway, D Reed, D Lyter, L Kingsley.   

Abstract

Specific cellular immune responses to human immunodeficiency virus type 1 (HIV-1) were assessed in mononuclear leukocyte cultures from homosexual men with documented, early phase HIV-1 infection. Cell cultures from men with a mean duration of 1.3 yr (range, 0.3 to 2.2 yr) of HIV-1 infection were treated with UV-inactivated, whole, purified HIV-1 Ag together with various concentrations of rIL-2. Cell supernatants were harvested after 5-day incubation and assayed for IFN activity against encephalomyocarditis virus in human WISH cells. IFN subtypes were characterized by neutralization of antiviral activity with antiserum specific for human IFN-gamma and IFN-alpha. Results showed that cultures from 68% (17 of 25) of the HIV-1-seropositive subjects produced "immune" IFN-gamma in response to whole HIV-1 Ag plus rIL-2. IFN-gamma was induced in only 20% (5 of 25) of cultures treated with HIV-1 Ag alone. Enhancement of HIV-1-specific IFN-gamma production by rIL-2 was synergistic rather than additive in that titers induced by the mixture were consistently higher than the sum of IFN titers induced by HIV-1 or rIL-2 alone. This effect was not demonstrable in cultures from 18 HIV-1-seronegative men. Similarly, HIV-1-immune specific augmentation of IFN-gamma production by rIL-2 was noted for PENV9, a recombinant HIV-1 envelope glycoprotein gp41 and gp120 fragment. Production of IFN-gamma may be an important, HIV-1-immune specific parameter in the host response to this retrovirus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452186

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.

Authors:  J C de Quiros; W L Shupert; A C McNeil; J C Gea-Banacloche; M Flanigan; A Savage; L Martino; E E Weiskopf; H Imamichi; Y M Zhang; J Adelsburger; R Stevens; P M Murphy; P A Zimmerman; C W Hallahan; R T Davey; M Connors
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.

Authors:  G Rappocciolo; J F Toso; D J Torpey; P Gupta; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

3.  Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals.

Authors:  Ruey-Chyi Su; Aida Sivro; Joshua Kimani; Walter Jaoko; Francis A Plummer; T Blake Ball
Journal:  Blood       Date:  2011-01-03       Impact factor: 22.113

Review 4.  Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  Giovanni Barillari; Barbara Ensoli
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

5.  Expression of defective virus and cytokine genes in murine AIDS.

Authors:  S C Cheung; S K Chattopadhyay; H C Morse; P M Pitha
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

6.  Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection.

Authors:  J Ferbas; J Navratil; A Logar; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

7.  Enhancement of natural killer cell activity in human immunodeficiency virus-infected subjects by in vitro treatment with biologic response modifier OK-432.

Authors:  X L Huang; Z Fan; T Murayama; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

8.  Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI).

Authors:  S J Bell; D A Cooper; B E Kemp; R R Doherty; R Penny
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.